Research and Markets: Analysis of AERS Data on AMD Therapeutics

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d19476/analysis_of_aers_d) has announced the addition of the "Analysis of AERS Data on AMD Therapeutics" report to their offering.

This report provides a detailed analysis on the adverse events reported against the prescribed AMD drugs namely Lucentis, Macugen and Visudyne for the treatment of Wet age related macular degeneration (Wet AMD). It covers in-depth, the various aspects of these drugs in terms of the consequences from their consumption, keeping in line with the real-time data registered in the FDA AERS database.

Age-related macular degeneration is a degenerative condition of the macula (the central retina). It is the most common cause of vision loss in the United States in those 50 or older, and its prevalence increases with age. AMD is caused by hardening of the arteries that nourish the retina. This deprives the sensitive retinal tissue of oxygen and nutrients that it needs to function and thrive. As a result, the central vision deteriorates. Besides affecting older populations, AMD occurs in whites and females in particular. The disease also can result as a side effect of some drugs, and it seems to run in families. Macular degeneration is diagnosed as either dry (non-neovascular) or wet (neovascular).

Dry AMD is an early stage of the disease and may result from the aging and thinning of macular tissues, depositing of pigment in the macula or a combination of the two processes. Wet AMD refers to growth of new blood vessels in an area, such as the macula, where the Wet they are not supposed to be. The dry form is more common than the wet, with about 85 percent of AMD patients diagnosed with dry AMD. The wet form of the disease usually leads to more serious vision loss.

Key Topics Covered:

• 1. Research overview and methodology
• 2. AMD drugs - An instant brief
• 3. A Bulletin on the "Miracle drugs" for the treatment of wet AMD
• 4. Drug risk assessment: From signals to regulatory actions
• 5. Research briefs
• 6. AMD treatment agents - An analysis of their cases and reports
• 7. The cardinal consequences of consuming AMD medications
• 8. Exclusive reactions of AMD medications
• 9. Cardiovascular and CNS related reactions - An intricate examination of the AMD medicaments
• 10. Eventuality of consuming AMD therapeutics
• 11. Conclusion
• 12. AMD drugs - Individual profiles
• 13. Glossary

Companies Mentioned:

• Genentech
• Eyetech Pharmaceuticals
• Pfizer
• Novartis opthalmics
• OSI pharmaceuticals
• Othera Pharmaceuticals
• QLT
• Isis Pharmaceuticals
• PR Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/d19476/analysis_of_aers_d